AU2009282958A1 - Calibration surface method for determination of analyte ratios - Google Patents
Calibration surface method for determination of analyte ratios Download PDFInfo
- Publication number
- AU2009282958A1 AU2009282958A1 AU2009282958A AU2009282958A AU2009282958A1 AU 2009282958 A1 AU2009282958 A1 AU 2009282958A1 AU 2009282958 A AU2009282958 A AU 2009282958A AU 2009282958 A AU2009282958 A AU 2009282958A AU 2009282958 A1 AU2009282958 A1 AU 2009282958A1
- Authority
- AU
- Australia
- Prior art keywords
- analytes
- responses
- analyte
- ratio
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 162
- 239000012491 analyte Substances 0.000 title claims description 113
- 230000004044 response Effects 0.000 claims description 113
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 230000009466 transformation Effects 0.000 claims description 37
- 230000008569 process Effects 0.000 claims description 27
- 102000001554 Hemoglobins Human genes 0.000 claims description 26
- 108010054147 Hemoglobins Proteins 0.000 claims description 26
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 13
- 230000006870 function Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 4
- 238000005251 capillar electrophoresis Methods 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 64
- 238000011088 calibration curve Methods 0.000 description 16
- 239000011324 bead Substances 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000000691 measurement method Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/196,132 | 2008-08-21 | ||
| US12/196,132 US8260556B2 (en) | 2008-08-21 | 2008-08-21 | Calibration surface method for determination on of analyte ratios |
| PCT/US2009/053746 WO2010021914A2 (en) | 2008-08-21 | 2009-08-13 | Calibration surface method for determination of analyte ratios |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2009282958A1 true AU2009282958A1 (en) | 2010-02-25 |
Family
ID=41697148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009282958A Abandoned AU2009282958A1 (en) | 2008-08-21 | 2009-08-13 | Calibration surface method for determination of analyte ratios |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8260556B2 (https=) |
| EP (1) | EP2316027A4 (https=) |
| JP (1) | JP5567567B2 (https=) |
| CN (1) | CN102159947B (https=) |
| AU (1) | AU2009282958A1 (https=) |
| CA (1) | CA2734741A1 (https=) |
| WO (1) | WO2010021914A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8260556B2 (en) | 2008-08-21 | 2012-09-04 | Bio-Rad Laboratories, Inc. | Calibration surface method for determination on of analyte ratios |
| US8603828B2 (en) | 2009-11-18 | 2013-12-10 | Bio-Rad Laboratories, Inc. | Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms |
| US8620590B2 (en) * | 2010-09-30 | 2013-12-31 | Bio-Rad Laboratories, Inc. | Dose surface method for determination of analyte ratios |
| WO2013039450A1 (en) * | 2011-09-14 | 2013-03-21 | Phadia Ab | Calibration reagent and method |
| US20150212054A1 (en) * | 2012-08-08 | 2015-07-30 | Paul Saunders | Compact multiple chromatographic media device |
| CA2900201C (en) | 2014-08-25 | 2025-01-07 | Bio-Rad Laboratories, Inc. | VALUE ASSIGNMENT TO CUSTOMIZABLE QUALITY CONTROLS |
| GB201517985D0 (en) * | 2015-10-12 | 2015-11-25 | Ge Healthcare Bio Sciences Ab | A method in a surface plasmon resonance biosensor system |
| CN106596209B (zh) * | 2015-10-14 | 2020-05-12 | 杭州量康科技有限公司 | 干血样本预处理及检测方法 |
| DE202018006591U1 (de) | 2017-08-18 | 2021-07-21 | Abbott Diabetes Care, Inc. | Systeme und Vorrichtungen betreffend die individualisierte Kalibrierung und/oder Herstellung von medizinischen Vorrichtungen |
| SG11202111365QA (en) * | 2019-05-17 | 2021-11-29 | Somalogic Inc | Controlling intersample analyte variability in complex biological matrices |
| EP4078168B1 (en) * | 2019-12-17 | 2026-04-01 | Roche Diagnostics GmbH | Method for calibrating at least one analytic device with multiple repeated hardware components |
| WO2024256703A1 (en) * | 2023-06-16 | 2024-12-19 | Waters Technologies Ireland Limited | Spectrometric analysis |
| GB2631006A (en) * | 2023-06-16 | 2024-12-18 | Waters Technologies Ireland Ltd | Spectrometric analysis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2228844C (en) * | 1995-08-07 | 2006-03-14 | Boehringer Mannheim Corporation | Biological fluid analysis using distance outlier detection |
| US5606164A (en) | 1996-01-16 | 1997-02-25 | Boehringer Mannheim Corporation | Method and apparatus for biological fluid analyte concentration measurement using generalized distance outlier detection |
| US6436721B1 (en) * | 1997-07-25 | 2002-08-20 | Bayer Corporation | Device and method for obtaining clinically significant analyte ratios |
| US6210971B1 (en) | 1999-01-25 | 2001-04-03 | Bayer Corporation | Assay for the detection of creatinine |
| JP4144117B2 (ja) * | 1999-06-04 | 2008-09-03 | 東ソー株式会社 | グルコースの測定方法及び測定装置 |
| US6898451B2 (en) * | 2001-03-21 | 2005-05-24 | Minformed, L.L.C. | Non-invasive blood analyte measuring system and method utilizing optical absorption |
| WO2002087431A1 (en) | 2001-05-01 | 2002-11-07 | Structural Bioinformatics, Inc. | Diagnosing inapparent diseases from common clinical tests using bayesian analysis |
| US6862534B2 (en) | 2001-12-14 | 2005-03-01 | Optiscan Biomedical Corporation | Method of determining an analyte concentration in a sample from an absorption spectrum |
| JP2005253478A (ja) * | 2002-03-18 | 2005-09-22 | Citizen Watch Co Ltd | ヘモグロビン分析装置 |
| US6977517B2 (en) * | 2002-05-20 | 2005-12-20 | Finisar Corporation | Laser production and product qualification via accelerated life testing based on statistical modeling |
| US7174198B2 (en) * | 2002-12-27 | 2007-02-06 | Igor Trofimov | Non-invasive detection of analytes in a complex matrix |
| US6968221B2 (en) * | 2003-03-14 | 2005-11-22 | Futrex, Inc. | Low-cost method and apparatus for non-invasively measuring blood glucose levels |
| CA2510277C (en) * | 2003-09-23 | 2012-07-24 | Epinex Diagnostics, Inc. | Rapid test for glycated albumin |
| US20050176089A1 (en) | 2003-12-04 | 2005-08-11 | Ehrlich Michael S. | Methods and devices for retrieving a subject's physiological history from a biological sample analysis |
| CN1938589B (zh) * | 2004-03-31 | 2011-12-28 | 拜尔健康护理有限责任公司 | 用于实现用于生物传感器的基于阈值的校正函数的方法和装置 |
| US20060281982A1 (en) * | 2005-06-14 | 2006-12-14 | Diasense, Inc. | Method and apparatus for the non-invasive sensing of glucose in a human subject |
| US8268625B2 (en) * | 2006-03-24 | 2012-09-18 | Arkray, Inc. | Method of measuring glycated hemoglobin concentration and concentration measuring apparatus |
| GB2436681B (en) * | 2006-03-31 | 2010-10-13 | Quotient Diagnostics Ltd | Fluorescent assay |
| US8260556B2 (en) | 2008-08-21 | 2012-09-04 | Bio-Rad Laboratories, Inc. | Calibration surface method for determination on of analyte ratios |
-
2008
- 2008-08-21 US US12/196,132 patent/US8260556B2/en not_active Expired - Fee Related
-
2009
- 2009-08-13 CA CA2734741A patent/CA2734741A1/en not_active Abandoned
- 2009-08-13 CN CN200980138015.1A patent/CN102159947B/zh not_active Expired - Fee Related
- 2009-08-13 EP EP09808625A patent/EP2316027A4/en not_active Withdrawn
- 2009-08-13 AU AU2009282958A patent/AU2009282958A1/en not_active Abandoned
- 2009-08-13 JP JP2011523882A patent/JP5567567B2/ja not_active Expired - Fee Related
- 2009-08-13 WO PCT/US2009/053746 patent/WO2010021914A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010021914A2 (en) | 2010-02-25 |
| JP5567567B2 (ja) | 2014-08-06 |
| EP2316027A4 (en) | 2011-11-09 |
| CN102159947A (zh) | 2011-08-17 |
| US20100049444A1 (en) | 2010-02-25 |
| CN102159947B (zh) | 2014-11-19 |
| EP2316027A2 (en) | 2011-05-04 |
| WO2010021914A3 (en) | 2010-05-14 |
| JP2012500401A (ja) | 2012-01-05 |
| US8260556B2 (en) | 2012-09-04 |
| CA2734741A1 (en) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8260556B2 (en) | Calibration surface method for determination on of analyte ratios | |
| English et al. | HbA1c method performance: the great success story of global standardization | |
| Marinova et al. | Multicenter evaluation of hemoglobin A1c assay on capillary electrophoresis | |
| Miller et al. | The evolving role of commutability in metrological traceability | |
| Bais et al. | Defining acceptable limits for the metrological traceability of specific measurands | |
| JP2012500401A5 (https=) | ||
| Delatour et al. | Trueness assessment of HbA1c routine assays: are processed EQA materials up to the job? | |
| Sriwimol et al. | Strong correlation and high comparability of capillary electrophoresis and three different methods for HbA1c measurement in a population without hemoglobinopathy | |
| EP2625519B1 (en) | Dose surface method for determination of analyte ratios | |
| Blasutig et al. | Analytical evaluation of the VITROS® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals | |
| Narinx et al. | A survey on measurement and reporting of total testosterone, sex hormone-binding globulin and free testosterone in clinical laboratories in Europe | |
| Kessler et al. | External Quality Assessment Scheme for reference laboratories–review of 8 years’ experience | |
| Kristiansen et al. | Traceability and uncertainty in analytical measurements | |
| Büttner | Reference methods as a basis for accurate measuring systems | |
| JPH0245150B2 (https=) | ||
| JP3279756B2 (ja) | 定量計算装置 | |
| Cole et al. | NIST Spectroscopic Measurement Standards | |
| Maier et al. | Target analyte quantification by isotope dilution LC-MS/MS directly referring to internal standard concentrations–validation for serum cortisol measurement | |
| Wilson et al. | Issues in immunoassay standardization: the ARCHITECT Folate model for intermethod harmonization | |
| Meguro et al. | Validation of the Japan Society of Clinical Chemistry (JSCC) recommended reference measurement procedure for glycated albumin determination | |
| Ramamohan et al. | Modeling, analysis and optimization of calibration uncertainty in clinical laboratories | |
| Rentfro et al. | Perspectives for Practice | |
| AU2009213995B2 (en) | Method for predicting a future property | |
| Guérin et al. | Evaluation of the long-term imprecision of the Capillarys 2 Flex Piercing® with serial differences in patient Hemoblogin A1c data: A comparison with two common immunoassays | |
| Blincko et al. | Non-separation assay for glycohemoglobin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |